Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

December 03, 2007 13:03 ET

Ambrilia Appoints Dr. Philippe Calais as New President and CEO

MONTREAL, QUEBEC--(Marketwire - Dec. 3, 2007) - Ambrilia Biopharma Inc. (TSX:AMB): Dr. Calais was elected to the roles of President, CEO and Board Member effective January 3, 2008, to efficiently lead Ambrilia's implementation of its new strategy. An accomplished biotech and pharma leader on an international level during the past 20 years, Dr. Calais has a broad range of expertise in management, drug development and global strategic operations. Dr. Calais' extensive knowledge and management experience in strategic alliances and drug development in anti-infectives are key in his current role, as well as his familiarity of U.S. markets.

Dr. Calais spent most of his career at Hoffman-La Roche (Switzerland) where he became the Global Business Leader for the anti-infective franchise. Dr. Calais moved to Canada to become General Manager of Servier Canada Inc., where he led a successful corporate reorganization. Prior to joining Ambrilia, Dr. Calais served as President of Global Business with Neurochem. Dr. Calais received his Pharmacy degree with industry specialization and his Doctorate in Pharmacy with Special Honours (Ph.D.) from the Universite Francois Rabelais in Tours, France. He received his CESAM degree in statistics as applied to medical research and general methodology from Universite Marie Curie in Paris. He also successfully completed an executive marketing program at INSEAD, France.

Editors Note: A photo for this release will be available on the CP picture wire via Marketwire.


Contact Information

  • Ambrilia Biopharma Inc.
    Julie M. Thibodeau
    Director, Communications
    514-751-2003 ext 235
    Source : Solutionpointcom Inc.
    Marius S. Brisson
    Cell : 514-972-2154